NCT07502001

Influence of HDM1005 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxin

A Phase I, Single-center, Open-Label, Single-Arm, Fixed-Sequence Study to Evaluate the Influence of HDM1005 on Gastric Emptying and Drug-Drug Interaction of HDM1005 and Metformin, Atorvastatin, Warfarin, and Digoxin in Overweight/Obese Adult Chinese Subjects

• Status: Not Yet Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 42 (estimated)
• Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to characterize the Influence of HDM1005 on gastric emptying and drug-drug interaction of HDM1005 and metformin, atorvastatin, warfarin, and digoxin in overweight/obese adult subjects.

Conditions

• Overweight
• Obesity

Interventions

Type	Name	Description
DRUG	Acetaminophen	Single dose; Administered orally
DRUG	Metformin	Single dose; Administered orally
DRUG	Warfarin	Single dose; Administered orally
DRUG	Atorvastatin	Single dose; Administered orally
DRUG	Digoxin	Single dose; Administered orally
DRUG	HDM1005 injection	Subcutaneous injection QW

Timeline

• Start date: 2026-04-08
• Primary completion: 2026-12-01
• Completion: 2027-06-02
• First posted: 2026-03-30
• Last updated: 2026-03-30

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study